Bayer AG (ADR) (OTCMKTS:BAYRY) and Kaiima Bio-Agritech Ltd., Moshav Sharona, Israel, announced their collaboration to develop advanced hybrid rice varieties. The multi-year project combines Bayer’s and Kaiima’s expertise in breeding and technology in order to increase growers’ productivity in important rice-cultivating countries. The goal of the collaboration is to focus on the breeding of new high-yielding hybrid rice varieties utilizing Bayer’s elite rice germplasm and Kaiima’s proprietary Enhanced Ploidy (EP) technology. Bayer AG (ADR) (OTCMKTS:BAYRY) on last trading day company shares ended up $141.05 .
Chinese police handed a bribery case against GlaxoSmithKline plc (ADR) (NYSE:GSK) China unit to prosecutors, accusing a British executive of ordering employees to illegally pay doctors, hospitals and medical associations to boost sales. Mark Reilly, a British national who previously led GSK’s China unit, allegedly helped set up and expand sales departments that offered the bribes, a Ministry of Public Security official said at a briefing in Beijing today, declining to identify himself. Glaxo in an e-mailed statement said it will continue to fully co-operate with the authorities. GlaxoSmithKline plc (ADR) (NYSE:GSK) shares advanced 0.69% in last trading session and ended the day on $55.52. GSK Gross Margin is 69.60% and its return on assets is 17.30 %. GlaxoSmithKline plc (ADR) (NYSE:GSK) quarterly performance is 3.87%.
Lundbeck A/S and Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) announced that the companies have entered into an agreement under which H. Lundbeck A/S (OTCMKTS:HLUYY) will acquire Chelsea Therapeutics International Ltd. Under the terms of the agreement, H. Lundbeck A/S (OTCMKTS:HLUYY) will commence a tender offer for all outstanding shares of Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), whereby Chelsea Therapeutics International Ltd. stockholders will be offered an upfront payment and contingent value rights (CVRs), representing a total potential consideration of up to USD 7.94 per share, or USD 658 million (approximately DKK 3.54 billion) on a fully diluted basis. H LUNDBECK A/S (OTCMKTS:HLUYY) shares moved down -0.70 % in last trading session and was closed at $28.79 , while trading in range of $ 28.79 -$28.84.
Valeant Pharmaceuticals International, Inc. responded to Allergan, Inc. (NYSE:AGN) rejection of Valeant’s proposal to combine with Allergan for $48.30 in cash and 0.83 shares of Valeant common stock for each Allergan share:Allergan, Inc. (NYSE:AGN) ended the last trading day at $161.28. Company weekly volatility is calculated as 2.27% and price to cash ratio as 13.59. Allergan, Inc. (NYSE:AGN) showed a negative weekly performance of -3.03%.
Teva Pharmaceuticals Industries Ltd., (ADR) (NYSE:TEVA) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s supplemental new drug application (sNDA) for a lower dose QNASL® (beclomethasone dipropionate) Nasal Aerosol for the treatment of seasonal and perennial allergic rhinitis in children 4-11 years of age. QNASL is a waterless intranasal corticosteroid spray currently available for the treatment of nasal symptoms of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in patients 12 years of age and older. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) net profit margin is 6.80% and weekly performance is 3.27%. On last trading day company shares ended up $51.20. Analysts mean target price for the company is $56.27. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) distance from 50-day simple moving average (SMA50) is 2.02%.